talquetamab,belantamab mafodotin
janssen,gsk
[' bari ', 'mmsm', 'monumental-1', 'fil,veral,12', 'belantamab', 'talquetamab', 'arca ', 'arca, (-arcade)']
main update from monumental-1 with talquetamab is the high response rate in patients with prior car t cell therapy 72% but only 44% if prior bispecifid- low numbers or t cell exhaustion or something else? #mmsm #ash22 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW